biotech / news / / scanx.trade
Emcure Pharmaceuticals delivered a strong performance in Q4 and full-year FY26, crossing the US$1 billion revenue milestone.
Emcure Pharmaceuticals crossed US$1 billion in revenue, growing 16.6% year-on-year to ₹9,204 Cr.
KEY POINTS
- International business drove growth, with Europe revenue up 35.8% YoY and Canada up 28.6%.
- R&D investment rose to ₹384 Cr in FY26, 4.2% of revenue, up from ₹287 Cr in FY25.
- Net debt increased to ₹1,054 Cr due to Zuventus consolidation and Manx acquisition.
- Emcure formed new partnerships with Novo Nordisk, Sanofi, and Roche for portfolio expansion.
COMPANIES
Summarized by Newsio from scanx.trade. How we summarize →